Novo Nordisk A/S Class BNovo Nordisk A/S Class BNovo Nordisk A/S Class B

Novo Nordisk A/S Class B

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪780.38 B‬PLN
13.32PLN
‪57.83 B‬PLN
‪166.31 B‬PLN
‪3.17 B‬
Beta (1Y)
1.58
Employees (FY)
‪76.3 K‬
Change (1Y)
‪+12.93 K‬ +20.41%
Revenue / Employee (1Y)
‪2.18 M‬PLN
Net income / Employee (1Y)
‪757.96 K‬PLN

About Novo Nordisk A/S Class B


CEO
Maziar Mike Doustdar
Headquarters
Bagsværd
Founded
1923
ISIN
DK0062498333
FIGI
BBG01VCLYS74
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037
Yield to maturity
3.70%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034
Yield to maturity
3.43%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033
Yield to maturity
3.26%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031
Yield to maturity
3.03%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030
Yield to maturity
2.96%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030
Yield to maturity
2.81%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028
Yield to maturity
2.73%
Maturity date
May 27, 2028
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029
Yield to maturity
2.73%
Maturity date
Jan 21, 2029
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028
Yield to maturity
2.63%
Maturity date
Jun 4, 2028
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026
Yield to maturity
2.48%
Maturity date
May 21, 2026
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027
Yield to maturity
2.39%
Maturity date
Sep 30, 2027

See all NVO bonds 

VXUS
Vanguard Total International Stock ETF
Weight
0.40%
Market value
‪2.28 B‬
USD
VEA
Vanguard FTSE Developed Markets ETF
Weight
0.56%
Market value
‪1.47 B‬
USD
IEFA
iShares Core MSCI EAFE ETF
Weight
0.68%
Market value
‪1.06 B‬
USD
EFA
iShares MSCI EAFE ETF
Weight
0.79%
Market value
‪530.09 M‬
USD
VGK
Vanguard FTSE Europe ETF
Weight
1.09%
Market value
‪387.21 M‬
USD
VEU
Vanguard FTSE All-World ex-US Index Fund
Weight
0.45%
Market value
‪341.12 M‬
USD
SCHF
Schwab International Equity ETF
Weight
0.61%
Market value
‪322.71 M‬
USD
SWDA
iShares Core MSCI World UCITS ETF
Weight
0.19%
Market value
‪246.18 M‬
USD
IWDG
iShares Core MSCI World UCITS ETF Hedged GBP
Weight
0.19%
Market value
‪246.18 M‬
USD
IWDD
iShares III PLC - iShares Core MSCI World UCITS ETF USD
Weight
0.19%
Market value
‪246.18 M‬
USD
IWLE
iShares Core MSCI World UCITS ETF Hedged (Dist)
Weight
0.19%
Market value
‪246.18 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of NVO is 175.98 PLN — it has decreased by −1.29% in the past 24 hours. Watch Novo Nordisk A/S Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange Novo Nordisk A/S Class B stocks are traded under the ticker NVO.
NVO stock has risen by 3.80% compared to the previous week, the month change is a −13.71% fall, over the last year Novo Nordisk A/S Class B has showed a −30.72% decrease.
We've gathered analysts' opinions on Novo Nordisk A/S Class B future price: according to them, NVO price has a max estimate of 305.19 PLN and a min estimate of 152.59 PLN. Watch NVO chart and read a more detailed Novo Nordisk A/S Class B stock forecast: see what analysts think of Novo Nordisk A/S Class B and suggest that you do with its stocks.
NVO reached its all-time high on Jun 16, 2025 with the price of 292.26 PLN, and its all-time low was 166.40 PLN and was reached on Aug 7, 2025. View more price dynamics on NVO chart.
See other stocks reaching their highest and lowest prices.
NVO stock is 1.87% volatile and has beta coefficient of 1.58. Track Novo Nordisk A/S Class B stock price on the chart and check out the list of the most volatile stocks — is Novo Nordisk A/S Class B there?
Today Novo Nordisk A/S Class B has the market capitalization of ‪786.78 B‬, it has increased by 9.16% over the last week.
Yes, you can track Novo Nordisk A/S Class B financials in yearly and quarterly reports right on TradingView.
Novo Nordisk A/S Class B is going to release the next earnings report on Feb 4, 2026. Keep track of upcoming events with our Earnings Calendar.
NVO earnings for the last quarter are 2.57 PLN per share, whereas the estimation was 2.79 PLN resulting in a −8.11% surprise. The estimated earnings for the next quarter are 3.40 PLN per share. See more details about Novo Nordisk A/S Class B earnings.
Novo Nordisk A/S Class B revenue for the last quarter amounts to ‪42.79 B‬ PLN, despite the estimated figure of ‪43.67 B‬ PLN. In the next quarter, revenue is expected to reach ‪44.54 B‬ PLN.
NVO net income for the last quarter is ‪11.42 B‬ PLN, while the quarter before that showed ‪15.07 B‬ PLN of net income which accounts for −24.23% change. Track more Novo Nordisk A/S Class B financial stats to get the full picture.
Novo Nordisk A/S Class B dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 18, 2025, the company has ‪76.3 K‬ employees. See our rating of the largest employees — is Novo Nordisk A/S Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo Nordisk A/S Class B EBITDA is ‪89.16 B‬ PLN, and current EBITDA margin is 50.95%. See more stats in Novo Nordisk A/S Class B financial statements.
Like other stocks, NVO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo Nordisk A/S Class B stock right from TradingView charts — choose your broker and connect to your account.